Leerink Partnrs Analysts Boost Earnings Estimates for TRVI

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Investment analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for Trevi Therapeutics in a research report issued to clients and investors on Tuesday, March 18th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings of ($0.10) per share for the quarter, up from their previous forecast of ($0.13). The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.45) EPS and FY2026 earnings at ($0.45) EPS.

A number of other analysts have also issued reports on the company. D. Boral Capital reiterated a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Oppenheimer boosted their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $9.00 to $29.00 in a research note on Monday, March 10th. Needham & Company LLC decreased their price objective on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and set a $12.50 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Seven analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $17.56.

Trevi Therapeutics Stock Performance

NASDAQ:TRVI opened at $6.47 on Friday. Trevi Therapeutics has a 52-week low of $2.30 and a 52-week high of $7.39. The firm has a market cap of $497.32 million, a price-to-earnings ratio of -14.70 and a beta of 0.90. The business’s fifty day moving average is $4.60 and its 200 day moving average is $3.75.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01.

Insider Buying and Selling

In related news, insider Farrell Simon sold 81,313 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the transaction, the insider now directly owns 76,900 shares in the company, valued at $519,075. The trade was a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 24.37% of the stock is owned by company insiders.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Summit Investment Advisors Inc. boosted its holdings in shares of Trevi Therapeutics by 84.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after purchasing an additional 2,894 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Trevi Therapeutics in the 4th quarter worth about $49,000. Squarepoint Ops LLC purchased a new position in shares of Trevi Therapeutics in the 4th quarter worth about $58,000. Finally, Two Sigma Advisers LP purchased a new position in shares of Trevi Therapeutics in the 4th quarter worth about $66,000. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.